ALTIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.22 USD | -6.48% |
|
-1.10% | -35.82% |
| May. 09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 | MT |
Presenter SpeechLiisa Bayko (Analysts)[Audio Gap]
The company's e...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Calendar
2024-05-14
- Citizens JMP Life Sciences Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
7.22
USD
Average target price
20.86
USD
Spread / Average Target
+188.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.82% | 512M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Transcript : Altimmune, Inc. - Special Call